Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2019 | Myeloma XI study update: KCRD for NDMM

Graham Jackson • 17 May 2019
COMy 2019
Multiple Myeloma Carfilzomib Cyclophosphamide Dexamethasone Lenalidomide
Myeloma XI

Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, reports promising outcomes from the Myeloma XI study (NCT01554852), where newly diagnosed multiple myeloma patients were administered the quadruplet of carfilzomib, cyclophosphamide, lenalidomide and dexamethasone (KCRD). This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Graham Jackson

0:58
Education gaps in CAR-T therapy
Graham Jackson • 13 May 2022
0:58
The efficacy of ixazomib for the treatment of R/R myeloma
Graham Jackson • 13 May 2022
1:09
Treatment holidays in multiple myeloma
Graham Jackson • 13 May 2022
1:10
Infection prophylaxis in multiple myeloma
Graham Jackson • 13 May 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals